Day One Biopharmaceuticals Inc
DAWN7.210USD
+0.220+3.15%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
738.53MMarket Cap
LossP/E TTM
More Details of Day One Biopharmaceuticals Inc Company
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
Company Info
Ticker SymbolDAWN
Company nameDay One Biopharmaceuticals Inc
IPO dateMay 27, 2021
CEODr. Jeremy Bender, Ph.D.
Number of employees181
Security typeOrdinary Share
Fiscal year-endMay 27
Address2000 Sierra Point Parkway, Suite 501
CityBRISBANE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94005
Phone16504840899
Websitehttps://dayonebio.com/
Ticker SymbolDAWN
IPO dateMay 27, 2021
CEODr. Jeremy Bender, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.80M
+0.87%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
66.94K
+13.04%
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
41.93K
+19.25%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Natalie C. Holles
Ms. Natalie C. Holles
Independent Director
Independent Director
--
--
Dr. John A. Josey, Ph.D.
Dr. John A. Josey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles N. York, II
Mr. Charles N. York, II
Chief Financial Officer, Chief Operating Officer, Secretary
Chief Financial Officer, Chief Operating Officer, Secretary
--
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.80M
+0.87%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
66.94K
+13.04%
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
41.93K
+19.25%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
30.76M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Access Industries, Inc.
12.62%
Fidelity Management & Research Company LLC
8.98%
BlackRock Institutional Trust Company, N.A.
6.64%
Atlas Venture
6.28%
The Vanguard Group, Inc.
6.02%
Other
59.47%
Shareholders
Shareholders
Proportion
Access Industries, Inc.
12.62%
Fidelity Management & Research Company LLC
8.98%
BlackRock Institutional Trust Company, N.A.
6.64%
Atlas Venture
6.28%
The Vanguard Group, Inc.
6.02%
Other
59.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.17%
Investment Advisor/Hedge Fund
25.22%
Hedge Fund
18.43%
Corporation
12.62%
Venture Capital
6.30%
Individual Investor
4.31%
Research Firm
3.94%
Pension Fund
0.26%
Bank and Trust
0.24%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
385
113.55M
110.86%
-15.47M
2025Q1
400
113.26M
111.74%
-16.79M
2024Q4
385
112.87M
111.38%
-9.38M
2024Q3
370
111.03M
112.52%
+6.48M
2024Q2
350
93.62M
107.11%
-6.88M
2024Q1
332
91.68M
104.96%
-18.10M
2023Q4
322
94.91M
109.07%
-11.77M
2023Q3
305
94.81M
109.41%
-11.39M
2023Q2
294
96.37M
113.78%
+8.76M
2023Q1
256
77.45M
105.60%
-6.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Access Industries, Inc.
12.93M
12.76%
--
--
Aug 01, 2024
Fidelity Management & Research Company LLC
11.38M
11.23%
+670.68K
+6.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.18M
5.11%
+127.47K
+2.52%
Mar 31, 2025
Atlas Venture
6.43M
6.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.93M
5.85%
+94.32K
+1.62%
Mar 31, 2025
Franklin Advisers, Inc.
3.98M
3.92%
+127.39K
+3.31%
Mar 31, 2025
Deerfield Management Company, L.P.
2.96M
2.92%
+364.71K
+14.05%
Mar 31, 2025
Pictet Asset Management Ltd.
3.64M
3.59%
+145.52K
+4.17%
Mar 31, 2025
Alyeska Investment Group, L.P.
4.06M
4.01%
+1.55M
+61.60%
Mar 31, 2025
Vestal Point Capital, LP
2.60M
2.56%
+1.16M
+80.43%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
